iTonic Holdings Ltd Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $523K+16.7% YoYTTM through 31 Dec 2025
Net Income -$5.1MTTM through 31 Dec 2025
Free Cash Flow -$3.2MTTM through 31 Dec 2025
Margins
| Current | |
|---|---|
| Gross Margin | 62.6% |
| EBITDA Margin | -980.3% |
| Operating Margin | -991.7% |
| Net Margin | -974.7% |
Returns
-83.3%ROE
-56.0%ROA
Balance Sheet Health
Current Ratio8.83x
Cash & Equivalents$1.5M
Quality Metrics
Altman Z-Score-0.61
Piotroski F-Score1 / 9
FCF Margin-618.6%
Multi-Year Trend
RevenueFY2025: $523K
Diluted EPS-$0.32TTMFY2025: $-0.32
Dividend
No dividend
Capital Allocation
R&D Spend$459.1K
Capex Intensity0.7%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Sales of FTTPS | $362.9K | -1.8% | |
| Sales of Medical Auxiliary Supplies | $160.2K | +103.7% |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.